KIT as a therapeutic target in neuroendocrine prostate cancer
- Author(s)
- Azad, AA; Kostos, L; Agarwal, N;
- Details
- Publication Year 2022-11-14,Volume 40,Issue #11,Page 1266-1268
- Journal Title
- Cancer Cell
- Publication Type
- Commentary
- Abstract
- Understanding lineage plasticity in prostate cancer cells is crucial to overcoming disease progression and therapeutic resistance. In this issue of Cancer Cell, Han et al. demonstrate that Foxa2 promotes luminal-to-neuroendocrine differentiation and that it also upregulates Kit expression in neuroendocrine cells. KIT signaling inhibition represents a promising therapeutic strategy in neuroendocrine prostate cancer.
- Keywords
- Male; Humans; *Prostatic Neoplasms/drug therapy/genetics/metabolism; *Carcinoma, Neuroendocrine/drug therapy/genetics; Signal Transduction; Cell Line, Tumor
- Department(s)
- Medical Oncology
- PubMed ID
- 36332623
- Publisher's Version
- https://doi.org/10.1016/j.ccell.2022.10.010
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-26 05:45:21
Last Modified: 2024-09-26 05:48:04